BiotechTube

E2814

Phase 1/2Completed
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease

Trial Timeline

Jun 28, 2021 → May 24, 2024

NCT ID
NCT04971733

About E2814

E2814 is a phase 1/2 stage product being developed by Eisai for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04971733. Target conditions include Alzheimer Disease.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer Disease were approved

Approved (20) Terminated (2) Active (0)
✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved
✅DonepezilEisaiApproved
✅DONEPEZIL HYDROCHLORIDEEisaiApproved
✅Donepezil HCLEisaiApproved
✅Donepezil HClEisaiApproved
✅Donepezil HydrochlorideEisaiApproved
✅AriceptEisaiApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04971733Phase 1/2Completed

Competing Products

20 competing products in Alzheimer Disease

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
21
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
LY450139 + PlaceboEli LillyPhase 3
40
Solanezumab + PlaceboEli LillyPhase 3
32
LY450139 dihydrate + placeboEli LillyPhase 2
35
Zagotenemab + PlaceboEli LillyPhase 2
35
Donanemab + Placebo + LY3202626Eli LillyPhase 2
35
Donanemab + PlaceboEli LillyPhase 3
47
GSK4527226AlectorPhase 2
29
AL002 + PlaceboAlectorPhase 2
25
GSK4527226AlectorPhase 2
32
AL002AlectorPhase 2
17
Solanezumab + PlaceboEli LillyPhase 3
32
donanemabEli LillyPhase 2
35
ATH-1017LeonaBioPhase 2/3
20
ATH-1017 + PlaceboLeonaBioPhase 2/3
28
ATH-1017 + PlaceboLeonaBioPhase 2
25
NDX-1017 + PlaceboLeonaBioPhase 1
19
simufilamCassava SciencesPhase 2
17
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
19